Showing 20 of 72 recruiting trials for “primary-vitreoretinal-large-b-cell-lymphoma”
RecruitingNCT06294652 ↗
AGMT Austrian Lymphoma Registry
👨⚕️ Richard Greil, MD, Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria📍 1 site📅 Started Feb 2024View details ↗
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
👨⚕️ Martin Wermke, Prof., Technische Universität Dresden (TUD)📍 1 site📅 Started Feb 2024View details ↗
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
👨⚕️ Samuel Yamshon, M.D., Weill Medical College of Cornell University📍 1 site📅 Started Oct 2023View details ↗
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
👨⚕️ lugui Qiu, MD, blood diseases hospital，chinese academy of medical sciences📍 1 site📅 Started Sep 2023View details ↗
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RecruitingNCT05831865 ↗
Frontline of ASCT in High-risk DLBCL
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingNCT05725720 ↗
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy
RecruitingNCT05377307 ↗
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Genotype-guided Treatment in DLBCL
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →